High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly (LLY) grew revenue 48% in Q2 2026, driven by Zepbound and Mounjaro. A more understated metric for investors to watch is pricing. Lilly's U.S. price fell 9% from a year earlier, excluding changes to rebate estimates. So far, volume covers that cut. The risk is the quarter it cannot.
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.
Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the second quarter of 2026.
Disparate but related tensions among the U.S., Canada and Iran continue to roil financial markets.
Amgen's (AMGN) experimental heart drug olpasiran may still show a meaningful reduction in major card
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.
The 563-patient study hit three efficacy endpoints, but investors still lack hazard ratios and regulatory timing.
Amgen (NASDAQ:AMGN) shares fell 4. 7% to $416.
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Stocks were on track to open lower on Tuesday as investors fretted about the disruption of oil shipments through the Strait of Hormuz. Dow Jones Industrial Average futures slumped 479 points, or 0.9%. S&P 500 futures dropped 0.4%.
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
Amgen said Monday its cholesterol buster, Repatha, reduced the risk of death by 20% in a study of more than 12,000 high-risk patients.
Generating $86,400 a year in dividends sounds like a number reserved for the ultra-wealthy, but the capital required swings dramatically depending on one variable most investors overlook before they build a single position.
The biotech raised its full-year revenue forecast to $38.2 billion–$39.4 billion after second-quarter revenue rose 10% to $10.1 billion
Wall Street is heading for another mixed session on Tuesday, with blue-chip gains offset by concerns about AI spending and Chinese competition weighing on some technology stocks. Dow Jones futures were up 317 points, or 0.6%, but the Nasdaq has been called 1% lower, with S&P 500 futures...
Stock Market Today: The Dow Jones index dropped Friday as Netflix stock plunged on earnings. SpaceX shares sold off on a canceled test flight.
Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...
In early June 2026, a federal judge granted Amgen a preliminary injunction blocking Colorado’s proposed 70% price cap on its rheumatoid arthritis drug Enbrel, while the company also initiated several voluntary Class II recalls of Corlanor and Sensipar batches in the United States over foreign substances and CGMP deviations. This mix of regulatory relief on Enbrel’s pricing and ongoing quality-related recalls raises important questions about how investors weigh pricing power against...
Amgen has initiated several product recalls in the US for Sensipar (cinacalcet) and Corlanor (ivabradine). The recalls involve multiple lots, dosage strengths, and large product quantities distributed nationwide. Regulators cited current good manufacturing practice (CGMP) deviations and contamination concerns affecting certain products. The pattern of recurring recalls extends beyond a single isolated lot or event. For investors following Amgen, ticker NasdaqGS:AMGN, the scale and...
US futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening. Dow Jones futures were up...
In the closing of the recent trading day, Amgen (AMGN) stood at $337.5, denoting a -2.05% move from the preceding trading day.
Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
